Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection (Anascorp)

Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection is an FDA-licensed reference biologic from Rare Disease Therapeutics, Inc. (RDT).

351(a) biologicBLA 125335 Rare Disease Therapeutics, Inc. (RDT)
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2011

Reference product

Originator biologic
351(a)BLA 125335

Anascorp Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection

Rare Disease Therapeutics, Inc. (RDT)

View full reference-product record
Approved
Marketing
Rx
Center
CBER
Patents
None listed

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection product.

    15 yr 4 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    8 yr 3 mo ago

Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.